There is a synthetic lethality between sacituzumab govitecan and a PARP inhibitor, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
There's a lot of biological and preclinical rationale for the combination of sacituzumab govitecan, a topoisomerase inhibitor, and talazoparib, a PARP inhibitor; there is a synthetic lethality, or synergy, between them, noted Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Transcript
How are the individual benefits of sacituzumab govitecan and talazoparib amplified in a combination treatment?
So, at virtual ESMO [European Society of Medical Oncology annual meeting], we presented the results of the ASCENT trial, which showed that patients who receive sacituzumab govitecan have a superior progression-free survival as compared to standard chemotherapy. The median progression-free survival was 5.6 months versus 1.7 months with standard chemotherapy. And even in terms of overall survival, patients who receive sacituzumab govitecan had an overall survival of 12.1 months as compared to 6.7 months with standard chemotherapy, with the hazard ratio of 0.48.
So, these results confirm that sacituzumab govitecan should be the new standard of care for patients with metastatic triple-negative breast cancer. The question is: moving forward, what should be done? And there's a lot of interest in combining this agent with other targeted therapies, including PARP inhibitors.
At ESMO, we also presented our trials in progress, a poster looking at the combination of sacituzumab govitecan with the PARP inhibitor, talazoparib. And there's a lot of biological and preclinical rationale for this combination. SN-38 is a topoisomerase inhibitor [that] induces single-strand DNA breaks, and in terms of repair of the DNA is reliant on the DNA repair pathways, including the PARP pathway. So, if you use a PARP inhibitor, it prevents the repair of the DNA and also prevents the cancer cells from repairing the DNA and replicating.
So, there's this synthetic lethality, or synergy, between SN-38, or sacituzumab govitecan, [and] a PARP inhibitor, so we're doing a phase 1B clinical trial combining these 2 agents, sacituzumab govitecan with a PARP inhibitor, talazoparib.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More